There is a lot of experimental evidence of the involvement of immune responses in the efficiency of many anti-cancer drugs. Are there data from clinical trials showing that immunodeficient patients do not respond well in terms of tumor regression after chemotherapy, after adjustment for similar tumor type and treatment?
Read Lisa Coussens research (organ Health and Science U), she and her lab changed the immune cells from helping cancer grow to fighting the cancer cell. Really great work.
Chatterjee R, Haines G, Perera D, et al. Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia. Hum Reprod 2000;15:762-6.
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., ... & Hodi, F. S. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical Cancer Research, 15(23), 7412-7420.
Shiao, S. L., Ganesan, A. P., Rugo, H. S., & Coussens, L. M. (2011). Immune microenvironments in solid tumors: new targets for therapy. Genes & development, 25(24), 2559-2572.
There is a whole study devoted to cancer treatment by Rituximab in immunodeficient patients. There are even cancer cell lines extracted from AIDS related Burkitt lymphoma.
Here is a pubmed link:
http://www.ncbi.nlm.nih.gov/pubmed/?term=rituximab+aids
Regards,
Galina
Thank you Galina, but my question was about conventional chemotherapy, as in:
http://www.ncbi.nlm.nih.gov/pubmed/18523649
- Badges
- Science topic